Aligos Therapeutics, Inc. short interest in 2022
In 2022, Aligos Therapeutics, Inc.'s disclosed short interest ran from 4.48% of shares outstanding on 14 Jan 2022 to 0.91% on 30 Dec 2022, a change of -3.57 percentage points. The year's high was 6.94% on 31 May 2022 and its low 0.79% on 30 Sep 2022, averaging 3.46% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.41 days on 15 Jun 2022. Full history: Aligos Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 4.48% (14 Jan 2022)
- End of year
- 0.91% (30 Dec 2022)
- Change
- -3.57 pp
- High
- 6.94% (31 May 2022)
- Low
- 0.79% (30 Sep 2022)
- Average
- 3.46%
- Highest days to cover
- 14.41 (15 Jun 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 4.48% | 1.96 | |
| 31 Jan 2022 | 4.76% | 2.69 | |
| 15 Feb 2022 | 4.93% | 3.37 | |
| 28 Feb 2022 | 4.95% | 8.12 | |
| 15 Mar 2022 | 5.22% | 7.21 | 10-K filed, results (8-K) |
| 31 Mar 2022 | 5.38% | 5.49 | |
| 14 Apr 2022 | 5.64% | 7.20 | |
| 29 Apr 2022 | 6.10% | 12.85 | |
| 13 May 2022 | 6.80% | 5.76 | 10-Q filed, results (8-K) |
| 31 May 2022 | 6.94% | 6.52 | |
| 15 Jun 2022 | 6.69% | 14.41 | |
| 30 Jun 2022 | 5.23% | 5.31 | |
| 15 Aug 2022 | 1.02% | 3.97 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 0.82% | 6.36 | |
| 15 Sep 2022 | 0.91% | 4.98 | |
| 30 Sep 2022 | 0.79% | 3.41 | |
| 14 Oct 2022 | 0.82% | 4.77 | |
| 31 Oct 2022 | 0.83% | 8.25 | |
| 15 Nov 2022 | 0.98% | 4.24 | 10-Q filed, results (8-K) |
| 30 Nov 2022 | 0.91% | 6.98 | |
| 15 Dec 2022 | 0.94% | 5.07 | |
| 30 Dec 2022 | 0.91% | 1.00 |
See also: Aligos Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.